SCI Abstract

search
+
Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies
Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies
Advances in modern molecular and genomic testing have spurred tremendous progress in our understanding of MDS pathogenesis...
From MRD To Match: the Role of Allogeneic Hematopoietic Cell Transplant in Philadelphia-Negative B-ALL
From MRD To Match: the Role of Allogeneic Hematopoietic Cell Transplant in Philadelphia-Negative B-ALL
Given the high risk of relapse for Philadelphia-negative (Ph-negative) B-cell acute lymphoblastic leukemia (ALL), allogene...
Targeting RUNX1 Germline Variants: Agents Under Investigation
Targeting RUNX1 Germline Variants: Agents Under Investigation
Despite increased recognition of FPDMM and advancements in genetic technologies that have improved carrier identification ...
Impact of Germline DNA Repair Mutations on Clonal Hematopoiesis and Myeloid Neoplasm Development
Impact of Germline DNA Repair Mutations on Clonal Hematopoiesis and Myeloid Neoplasm Development
Clonal hematopoiesis (CH) arises from the expansion of a single hematopoietic stem cell harboring somatic mutations that c...
Understanding Triple Negative Myeloproliferative Neoplasms and Identifying Molecular Drivers
Understanding Triple Negative Myeloproliferative Neoplasms and Identifying Molecular Drivers
Triple-negative (TN) myeloproliferative neoplasms (MPNs), defined by the absence of canonical driver JAK2, CALR and MPL mu...
Advances and Controversies in the Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Navigating First-Line Therapies
Advances and Controversies in the Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Navigating First-Line Therapies
The goal of this review is to provide an updated synthesis of therapeutic advances and remaining controversies in the mana...
New Approaches for Measurable Residual Disease Assessment in Multiple Myeloma: Integrating NGS, Mass Spectrometry, and Next-Generation Flow Cytometry to Monitor Treatment Response
New Approaches for Measurable Residual Disease Assessment in Multiple Myeloma: Integrating NGS, Mass Spectrometry, and Next-Generation Flow Cytometry to Monitor Treatment Response
Measurable residual disease (MRD) has emerged as the strongest prognostic biomarker in multiple myeloma (MM), providing a ...
When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia
When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia
Targeted therapies have revolutionized the treatment of chronic lymphocytic leukemia (CLL), however the disease remains in...
Molecular Pathogenesis and Targeted Therapies for Myeloproliferative Hypereosinophilic Neoplasms
Molecular Pathogenesis and Targeted Therapies for Myeloproliferative Hypereosinophilic Neoplasms
This review examines the rapidly evolving landscape of myeloproliferative hypereosinophilic syndromes (HES) and related ne...
Clonal Signatures of Telomere Biology Disorders
Clonal Signatures of Telomere Biology Disorders
In inherited bone marrow failure syndromes (IBMFS), clonal hematopoiesis (CH) has been increasingly recognized as a molecu...
Germline DDX41 Variants: Current Understanding and Future Directions
Germline DDX41 Variants: Current Understanding and Future Directions
To sumarize, provide an overview, and critically assess the currently available literature pertaining to the detection, ma...
Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia
Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia
Despite the success of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML), resistance an...
BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance
BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance
BRAF alterations are uncommon in chronic lymphocytic leukemia (CLL), yet increasing use of broad genomic profiling has ide...
Use of Patient-Centered Technology and Digital Interventions in Pediatric and Adult Patients with Hematologic Malignancies
Use of Patient-Centered Technology and Digital Interventions in Pediatric and Adult Patients with Hematologic Malignancies
As society continues to advance in technology, it is important to address how this advancement can impact and enhance pati...
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia
Waldenström macroglobulinemia is a rare non-Hodgkin lymphoma (NHL) characterized by lymphoplasmacytic bone marrow inf...
Systemic Mastocytosis: State of the Art
Systemic Mastocytosis: State of the Art
Since identification of Systemic mastocytosis (SM) as a distinct disease entity by the World Health Organisation (WHO), th...
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals
In this review, we aim to explore the optimal approach to patients presenting with eosinophilia, considering recent advanc...
JAK Inhibitors for Myelofibrosis: Strengths and Limitations
JAK Inhibitors for Myelofibrosis: Strengths and Limitations
The landscape of myelofibrosis (MF) has changed since the discovery of the JAK2 V617F mutation and subsequent development ...
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma
The introduction of bispecific antibodies is one of the most significant recent advances in the treatment of relapsed/refr...
Disparities in Clinical Trial Enrollment– Focus on CAR-T and Bispecific Antibody Therapies
Disparities in Clinical Trial Enrollment– Focus on CAR-T and Bispecific Antibody Therapies
Recent studies show that unresolved disparities hinder enrollment to clinical trials, equitable distribution of treatments...
Monoclonal Gammopathy-Associated Neuropathy
Monoclonal Gammopathy-Associated Neuropathy
Peripheral neuropathy (PN) is more commonly seen in individuals with monoclonal gammopathies, especially in patients with ...
Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies
Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies
Multiple myeloma is a chronic malignancy and with evolving treatment options, understanding the economic burden and cost-e...
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications
More than a decade following the discovery of Calreticulin (CALR) mutations as drivers of myeloproliferative neoplasms (MP...
Blinatumomab in Practice
Blinatumomab in Practice
Acute lymphoblastic leukemia (ALL) is a rare hematologic neoplasm in adults, with most cases defined by pathology related ...
Novel Biomarkers and Molecular Targets in ALL
Novel Biomarkers and Molecular Targets in ALL
Acute lymphoblastic leukemia (ALL) is a widely heterogeneous disease in terms of genomic alterations, treatment options, a...
Unlocking the Potential of Artificial Intelligence in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Unlocking the Potential of Artificial Intelligence in Acute Myeloid Leukemia and Myelodysplastic Syndromes
This review aims to elucidate the transformative impact and potential of machine learning (ML) in the diagnosis, prognosis...
Measurable Residual Disease Monitoring in Lymphoma
Measurable Residual Disease Monitoring in Lymphoma
The utility of analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and disease in the bone marrow as ...
Experimental and Computational Approaches to Measure Telomere Length: Recent Advances and Future Directions
Experimental and Computational Approaches to Measure Telomere Length: Recent Advances and Future Directions
The length of telomeres, protective structures at the chromosome ends, is a well-established biomarker for pathological co...
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders
Mature T/NK-cell neoplasms comprise a heterogeneous group of diseases with diverse clinical, histopathologic, immunophenot...
Genetic Counseling and Family Screening Recommendations in Patients with Telomere Biology Disorders
Genetic Counseling and Family Screening Recommendations in Patients with Telomere Biology Disorders
Telomere biology disorders (TBDs) encompass a spectrum of genetic diseases with a common pathogenesis of defects in telome...
Load More
format_indent_increase